Evidence map›Paper›PMID 38539263›Full record

ArticleEuropean journal of medical research2024

Comprehensive analysis of the prognostic value and immunological role of IDO1 gene in pan-cancer.

Kaili Lin, Yongfeng Wang, Fangyu Liu, Taifu You, Xiongxiong Liu, Runzhang Liu, Zeyang Li, Chunyu Zhen, Yunxia Zhang, Xingguang Liu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Kaili Lin *Lanzhou First People's Hospital, Lanzhou, 730000, Gansu, China.
Yongfeng Wang *The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, China.
Fangyu Liu *The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, China.
Taifu YouThe First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, China.
Xiongxiong LiuThe First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, China.
Runzhang LiuThe First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, China.
Zeyang LiThe First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, China.
Chunyu ZhenThe First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, China.
Yunxia ZhangThe First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, China.
Xingguang LiuThe First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, China. chenhongkouqiang@126.com.
Hui CaiGeneral Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, 204 Donggang West Road, Lanzhou, 730000, Gansu, China. caialonteam@163.com.ORCID http://orcid.org/0000-0001-5857-1744
Lanzhou University · CNGansu Provincial Hospital · CNFirst Hospital of Lanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIt has been demonstrated that IDO1, a target of immune checkpoint inhibition, functions as an oncogene in the majority of human malignancies. IDO1's function in human pan-cancers hasn't been thoroughly studied, though. MATERIALS AND

methodsThe Kaplan-Meier (K-M) and COX analyses were applied to the survival analysis. Furthermore, we used Spearman's correlation analysis to examine the associations between IDO1 and microsatellite instability (MSI), DNA methyltransferases (DNMTs), tumor mutational burden (TMB), the associated genes of mismatch repair (MMR), and immune checkpoint biomarkers. Moreover, immunohistochemical analysis and qRT-PCR were used to evaluate IDO1's expression in pan-cancer cells.

resultsThe findings of this study reveal that IDO1 has abnormal expression in a number of malignancies and is related to the prognosis for UVM, LGG, KIRP, GBM, LAML, OV, READ, MESO, SARC, SKCM, and HNSC. Furthermore, the aberrant IDO1 expression was connected to the TMB, MSI, MMR, drug sensitivity, immune cells infiltrating, and tumor immune microenvironment across a variety of cancer types. The PCR results showed that in contrast to normal cells, IDO1 was found to be significantly highly expressed in breast cancer cells and hepatocellular carcinoma cells, and significantly lowly expressed in gastric cancer cells.

conclusionThe clinical treatment of IDO1 is now better supported by a theoretical basis and guidelines provided by our study.

Indexed as

Stomach NeoplasmsCell LineDNA MethylationHumansPrognosisTumor MicroenvironmentBioinformatics analysisCancersIDO1Prognosis

Identifiers

PMID38539263
PMCPMC10967207
OpenAlexW4393231759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.